Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results

Peer Review reports

Original Submission
11 Dec 2012	Submitted	Original manuscript
19 Feb 2013	Reviewed	Reviewer Report - Giovanni Guaraldi
6 Mar 2013	Reviewed	Reviewer Report - Giustino Parruti
1 May 2013	Author responded	Author comments - Belinda Ha
Resubmission - Version 2
1 May 2013	Submitted	Manuscript version 2
21 May 2013	Reviewed	Reviewer Report - Giustino Parruti
Resubmission - Version 3
	Submitted	Manuscript version 3
Publishing
24 May 2013	Editorially accepted
7 Jun 2013	Article published	10.1186/1471-2334-13-269

Back to article page